By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regen BioPharma  

4700 Spring Street
Suite 304
La Mesa  California  91942  U.S.A.
Phone: 619-702-1404 Fax: 619-330-2328


Company News
Regen BioPharma Submits Response To FDA Questions On Hemaxellerate Investigational New Drug Application 11/17/2015 7:36:39 AM
Regen BioPharma Initiates NR2F6 T Cell Immunotherapy Preclinical Program With Dr. Santosh Kesari, Director Of Neuro-Oncology At John Wayne Cancer Institute 11/12/2015 8:43:08 AM
Regen BioPharma Files Patent Application On Personalized Checkpoint Inhibitor Cancer Immunotherapy 11/4/2015 10:34:26 AM
Regen BioPharma Announces Appointment Of Dr. Harry Lander As President 10/13/2015 10:24:17 AM
Regen BioPharma Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers 9/29/2015 8:21:10 AM
Regen BioPharma Director Of Molecular Therapeutics To Speak At Stem Cell Conference Regarding Leukemia Research Being Conducted By The Company 9/28/2015 12:52:05 PM
Regen BioPharma Announces Positive Results From GLP Safety Study For HemaXellerate 9/28/2015 6:06:41 AM
Regen BioPharma Initiates Small Molecule Hit Validation Study On Cancer Stem Cell Target Gene 9/23/2015 11:39:13 AM
Regen BioPharma Files Utility Patent Application On Immune Based Therapy For Cancer 9/16/2015 8:48:09 AM
Regen BioPharma Develops BORIS Gene Silencing Based Treatment For Unresectable Liver Cancer 8/31/2015 6:51:34 AM